Como ideas de inversión particulares, destacan la compra de bonos públicos argentinos y su entrada en las acciones de la farmacéutica Novo Nordisk ... de renta fija. Sin embargo, Rafael ...

Sin embargo, es incierto que el proceso continúe ... noviembre de 2023 y el 1 de octubre de 2024. En un comunicado de Novo Nordisk, que fabrica Ozempic y Wegovy, la farmacéutica dijo que está ...

Análisis DAFO de Eli Lilly: sus acciones se disparan por el éxito de un fármaco contra la diabetes, con la vista puesta en nuevos mercados ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

New York, New York-- (Newsfile Corp. - February 5, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.